Published in J Clin Oncol on April 01, 2013
Stereotactic Body Radiation Therapy (SBRT) Hepatocellular Carcinoma (COLD 2) | NCT00914355
Stereotactic Radiotherapy (SRT) Liver (COLD 1) | NCT00152906
Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma. J Clin Oncol (2015) 1.86
The relative biological effectiveness for carbon and oxygen ion beams using the raster-scanning technique in hepatocellular carcinoma cell lines. PLoS One (2014) 1.51
High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma. Radiat Oncol (2013) 1.34
2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma. Gut Liver (2015) 1.23
2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma. Korean J Radiol (2015) 1.14
Role of stereotactic body radiation therapy for hepatocellular carcinoma. World J Gastroenterol (2014) 1.06
Role of radiotherapy in the management of hepatocellular carcinoma: A systematic review. World J Hepatol (2015) 1.01
Stereotactic body radiation therapy for hepatocellular carcinoma: prognostic factors of local control, overall survival, and toxicity. PLoS One (2013) 1.00
Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. J Clin Oncol (2015) 0.96
Adjuvant stereotactic body radiotherapy following transarterial chemoembolization in patients with non-resectable hepatocellular carcinoma tumours of ≥ 3 cm. HPB (Oxford) (2014) 0.95
The tolerance of gastrointestinal organs to stereotactic body radiation therapy: what do we know so far? J Gastrointest Oncol (2014) 0.93
Gastrointestinal Toxicities With Combined Antiangiogenic and Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys (2015) 0.93
The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT). J Cancer Res Clin Oncol (2015) 0.89
Feasibility of stereotactic body radiation therapy with volumetric modulated arc therapy and high intensity photon beams for hepatocellular carcinoma patients. Radiat Oncol (2014) 0.89
Minimally invasive local therapies for liver cancer. Cancer Biol Med (2014) 0.88
Consensus for Radiotherapy in Hepatocellular Carcinoma from The 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014): Current Practice and Future Clinical Trials. Liver Cancer (2016) 0.87
Radiation Therapy Intensification for Solid Tumors: A Systematic Review of Randomized Trials. Int J Radiat Oncol Biol Phys (2015) 0.87
Interobserver variability in target definition for hepatocellular carcinoma with and without portal vein thrombus: radiation therapy oncology group consensus guidelines. Int J Radiat Oncol Biol Phys (2014) 0.86
Is Stereotactic Body Radiotherapy Better Than Radiofrequency Ablation for the Treatment of Hepatocellular Carcinoma? J Clin Oncol (2016) 0.85
Survival outcomes after stereotactic body radiotherapy for 79 Japanese patients with hepatocellular carcinoma. J Radiat Res (2015) 0.83
Evaluation of inter- and intrafractional motion of liver tumors using interstitial markers and implantable electromagnetic radiotransmitters in the context of image-guided radiotherapy (IGRT) - the ESMERALDA trial. Radiat Oncol (2015) 0.83
Stereotactic body radiation therapy in hepatocellular carcinoma: Optimal treatment strategies based on liver segmentation and functional hepatic reserve. Rep Pract Oncol Radiother (2015) 0.82
Radiation therapy for liver tumors: ready for inclusion in guidelines? Oncologist (2014) 0.82
Role of stereotactic body radiotherapy for oligometastasis from colorectal cancer. World J Gastroenterol (2014) 0.82
[Stereotactic body radiotherapy for the treatment of hepatocellular cancer. Pooled analysis of two phase I/II trials]. Strahlenther Onkol (2013) 0.82
Management of recurrent hepatocellular carcinoma after liver transplant. World J Hepatol (2015) 0.81
Recall radiation dermatitis by sorafenib following stereotactic body radiation therapy. Onco Targets Ther (2014) 0.80
Image-guided therapies in the treatment of hepatocellular carcinoma: A multidisciplinary perspective. World J Hepatol (2015) 0.80
Dose escalated liver stereotactic body radiation therapy at the mean respiratory position. Int J Radiat Oncol Biol Phys (2014) 0.80
Dosimetric comparison of carbon ion radiotherapy and stereotactic body radiotherapy with photon beams for the treatment of hepatocellular carcinoma. Radiat Oncol (2015) 0.80
Hong Kong consensus recommendations on the management of hepatocellular carcinoma. Liver Cancer (2015) 0.80
Reducing the probability of radiation-induced hepatic toxicity by changing the treatment modality from helical tomotherapy to fixed-beam intensity-modulated radiotherapy. Oncotarget (2015) 0.79
Multidisciplinary perspective of hepatocellular carcinoma: A Pacific Northwest experience. World J Hepatol (2015) 0.79
A prospective feasibility study of respiratory-gated proton beam therapy for liver tumors. Pract Radiat Oncol (2013) 0.79
Role of external beam radiation therapy in management of hepatocellular carcinoma. J Clin Exp Hepatol (2014) 0.79
Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma. Liver Cancer (2014) 0.79
Inferior vena cava tumor thrombus that directly infiltrated from paracaval lymph node metastases in a patient with recurrent hepatocellular carcinoma. World J Surg Oncol (2013) 0.78
Cyberknife treatment for advanced or terminal stage hepatocellular carcinoma. World J Gastroenterol (2015) 0.78
Bone marrow-derived stromal cell therapy in cirrhosis: clinical evidence, cellular mechanisms, and implications for the treatment of hepatocellular carcinoma. Int J Radiat Oncol Biol Phys (2014) 0.78
Stereotactic body radiotherapy for primary hepatic malignancies - Report of a phase I/II institutional study. Radiother Oncol (2016) 0.78
Long-term pathological and immunohistochemical features in the liver after intraoperative whole-liver irradiation in rats. J Radiat Res (2014) 0.77
Differential regulation of ferritin subunits and iron transport proteins: an effect of targeted hepatic X-irradiation. Biomed Res Int (2013) 0.77
Radiotherapy as valid modality for hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol (2016) 0.77
Technical advances in external radiotherapy for hepatocellular carcinoma. World J Gastroenterol (2016) 0.77
Stereotactic body radiation therapy as a derivative of stereotactic radiosurgery: clinically independent but with enduring common themes. J Clin Oncol (2014) 0.76
The Role of Hypofractionated Radiation Therapy with Photons, Protons, and Heavy Ions for Treating Extracranial Lesions. Front Oncol (2016) 0.76
Low Hepatic Toxicity in Primary and Metastatic Liver Cancers after Stereotactic Ablative Radiotherapy Using 3 Fractions. J Korean Med Sci (2015) 0.76
Liver-Directed Radiotherapy for Hepatocellular Carcinoma. Liver Cancer (2016) 0.76
Identification of Biologically Effective Dose-Volumetric Parameters That Predict Radiation-Induced Hepatic Toxicity in Patients Treated With Helical Tomotherapy for Unresectable Locally Advanced Hepatocellular Carcinoma. Medicine (Baltimore) (2015) 0.76
Eastern Canadian Gastrointestinal Cancer Consensus Conference 2016. Curr Oncol (2016) 0.75
External beam radiotherapy for unresectable hepatocellular carcinoma, an international multicenter phase I trial, SAKK 77/07 and SASL 26. Radiat Oncol (2017) 0.75
Image-guided high-dose-rate brachytherapy of malignancies in various inner organs - technique, indications, and perspectives. J Contemp Brachytherapy (2016) 0.75
CyberKnife Radiosurgery - Value as an Adjunct to Surgical Treatment of HCC? Cureus (2016) 0.75
Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cm. BMC Cancer (2016) 0.75
Stereotactic Body Radiotherapy for Hepatocellular Carcinoma Resulting in a Durable Relapse-Free Survival: A Case Report. Cureus (2016) 0.75
Radiofrequency ablation versus stereotactic body radiotherapy for small hepatocellular carcinoma: a Markov model-based analysis. Cancer Med (2016) 0.75
Practical patterns for stereotactic body radiotherapy to hepatocellular carcinoma in Korea: a survey of the Korean Stereotactic Radiosurgery Group. Jpn J Clin Oncol (2016) 0.75
Conformal external beam radiation or selective internal radiation therapy-a comparison of treatment outcomes for hepatocellular carcinoma. J Gastrointest Oncol (2016) 0.75
Metabolic syndrome-related hepatocellular carcinoma treated by volumetric modulated arc therapy. Curr Oncol (2014) 0.75
Charged particle therapy for hepatocellular carcinoma: a commentary on a recently published meta-analysis. Ann Transl Med (2015) 0.75
Long-term outcomes of proton beam therapy in patients with previously untreated hepatocellular carcinoma. Cancer Sci (2016) 0.75
Do Biliary Complications after Hypofractionated Radiation Therapy in Hepatocellular Carcinoma Matter? Cancer Res Treat (2015) 0.75
Loco-regional therapies for patients with hepatocellular carcinoma awaiting liver transplantation: Selecting an optimal therapy. World J Transplant (2016) 0.75
Stereotactic Body Radiotherapy for Inoperable Liver Tumors: Results of a Single Institutional Experience. Cureus (2016) 0.75
Clinical outcomes and prognostic factors of cyberknife stereotactic body radiation therapy for unresectable hepatocellular carcinoma. BMC Cancer (2016) 0.75
Radiotherapy and Sorafenib in the Management of Patients with Hepatocellular Carcinoma Have Led to Improved Survival: A Single Center Experience. J Cancer (2016) 0.75
Therapeutic Strategies in HCC: Radiation Modalities. Biomed Res Int (2016) 0.75
Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma. Radiat Oncol (2016) 0.75
How to Improve Therapeutic Ratio in Radiotherapy of HCC. Liver Cancer (2016) 0.75
Radiotherapy for hepatocellular carcinoma with tumor vascular thrombus: ready for prime time? J Clin Oncol (2013) 0.75
Reply to Yang et al and De Bari et al. J Clin Oncol (2016) 0.75
Combination of Photon and Carbon Ion Irradiation with Targeted Therapy Substances Temsirolimus and Gemcitabine in Hepatocellular Carcinoma Cell Lines. Front Oncol (2017) 0.75
Management of liver cancer. The Surgeon's point of view. Rep Pract Oncol Radiother (2017) 0.75
Imaged-guided liver stereotactic body radiotherapy using VMAT and real-time adaptive tumor gating. Concerns about technique and preliminary clinical results. Rep Pract Oncol Radiother (2016) 0.75
Radiation therapy for hepatobiliary malignancies. J Gastrointest Oncol (2017) 0.75
Strategies to tackle the challenges of external beam radiotherapy for liver tumors. World J Hepatol (2017) 0.75
Excellent local control and tolerance profile after stereotactic body radiotherapy of advanced hepatocellular carcinoma. Radiat Oncol (2017) 0.75
NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017. J Natl Compr Canc Netw (2017) 0.75
Interobserver variability in target volume delineation of hepatocellular carcinoma : An analysis of the working group "Stereotactic Radiotherapy" of the German Society for Radiation Oncology (DEGRO). Strahlenther Onkol (2017) 0.75
Management of hepatocellular carcinoma: an update. Hepatology (2011) 33.57
Management of hepatocellular carcinoma. Hepatology (2005) 27.42
Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol (2009) 8.16
Screening for Occult Cancer in Unprovoked Venous Thromboembolism. N Engl J Med (2015) 7.39
Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA (2010) 4.71
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol (2012) 3.88
Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. J Clin Oncol (2013) 3.76
Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol (2013) 3.71
Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol (2012) 3.56
Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Clin Oncol (2010) 3.55
Objective assessment of swallowing dysfunction and aspiration after radiation concurrent with chemotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys (2002) 3.39
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol (2012) 3.04
Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol (2008) 3.02
Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology (2003) 2.90
Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. Lancet Oncol (2012) 2.84
Comprehensive MicroRNA profiling for head and neck squamous cell carcinomas. Clin Cancer Res (2010) 2.79
Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol (2009) 2.78
Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma. J Clin Oncol (2009) 2.74
The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol (2010) 2.73
Radiation dose-volume effects in the stomach and small bowel. Int J Radiat Oncol Biol Phys (2010) 2.69
Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol (2007) 2.58
Patient self-reports of symptoms and clinician ratings as predictors of overall cancer survival. J Natl Cancer Inst (2011) 2.56
Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: a large retrospective study. Eur J Cancer (2012) 2.54
Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol (2006) 2.49
Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology (2013) 2.46
Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol (2003) 2.42
Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol (2008) 2.40
Radiation-associated liver injury. Int J Radiat Oncol Biol Phys (2010) 2.39
Change in diffusion weighted MRI during liver cancer radiotherapy: preliminary observations. Acta Oncol (2009) 2.33
Follow-up of patients with curatively resected colorectal cancer: a practice guideline. BMC Cancer (2003) 2.26
Indeterminate 1-2-cm nodules found on hepatocellular carcinoma surveillance: biopsy for all, some, or none? Hepatology (2011) 2.26
The prevention and management of acute skin reactions related to radiation therapy: a systematic review and practice guideline. Support Care Cancer (2006) 2.22
Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J Clin Oncol (2005) 2.20
Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol (2010) 2.12
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer (2010) 2.10
Recurrences near base of skull after IMRT for head-and-neck cancer: implications for target delineation in high neck and for parotid gland sparing. Int J Radiat Oncol Biol Phys (2004) 2.00
Postoperative intensity-modulated radiotherapy following surgery for oral cavity squamous cell carcinoma: patterns of failure. Oral Oncol (2012) 1.98
Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis. Cancer (2011) 1.87
Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114. J Clin Oncol (2004) 1.86
Radiotherapy for liver metastases: a review of evidence. Int J Radiat Oncol Biol Phys (2012) 1.85
IMRT for adjuvant radiation in gastric cancer: a preferred plan? Int J Radiat Oncol Biol Phys (2005) 1.84
Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology (2010) 1.80
Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases. Cochrane Database Syst Rev (2012) 1.79
Stage-specific effect of adjuvant therapy following gastric cancer resection: a population-based analysis of 4,041 patients. Ann Surg Oncol (2007) 1.78
MicroRNA-301 mediates proliferation and invasion in human breast cancer. Cancer Res (2011) 1.75
Assessment of a model-based deformable image registration approach for radiation therapy planning. Int J Radiat Oncol Biol Phys (2007) 1.75
Radiation therapy for hepatocellular carcinoma: from palliation to cure. Cancer (2006) 1.71
Pelvic normal tissue contouring guidelines for radiation therapy: a Radiation Therapy Oncology Group consensus panel atlas. Int J Radiat Oncol Biol Phys (2012) 1.70
Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy. Urology (2010) 1.68
Health-related quality of life associated with irritable bowel syndrome: comparison with other chronic diseases. Clin Ther (2002) 1.67
Prospective comparison of breast pain in patients participating in a randomized trial of breast-conserving surgery and tamoxifen with or without radiotherapy. Int J Radiat Oncol Biol Phys (2003) 1.67
Health care costs associated with hepatocellular carcinoma: a population-based study. Hepatology (2013) 1.63
Recurrence of hepatocellular carcinoma. N Engl J Med (2008) 1.60
Burden of disease and cost of chronic hepatitis C infection in Canada. Can J Gastroenterol Hepatol (2014) 1.59
Protease nexin 1 inhibits hedgehog signaling in prostate adenocarcinoma. J Clin Invest (2012) 1.57
Hepatocellular carcinoma radiation therapy: review of evidence and future opportunities. Int J Radiat Oncol Biol Phys (2012) 1.55
Postradiotherapy quality of life for head-and-neck cancer patients is independent of xerostomia. Int J Radiat Oncol Biol Phys (2005) 1.54
Radiotherapeutic management of brain metastases: a systematic review and meta-analysis. Cancer Treat Rev (2005) 1.54
A new strategy for the site-specific modification of proteins in vivo. Biochemistry (2003) 1.52
Sunitinib rechallenge in metastatic renal cell carcinoma patients. Cancer (2010) 1.52
Hepatocellular carcinoma (HCC): a global perspective. J Clin Gastroenterol (2010) 1.49
Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis. Am J Gastroenterol (2007) 1.49
Atypical clinical behavior of p16-confirmed HPV-related oropharyngeal squamous cell carcinoma treated with radical radiotherapy. Int J Radiat Oncol Biol Phys (2010) 1.49
Needle tract seeding after radiofrequency ablation of hepatic tumors. J Vasc Interv Radiol (2005) 1.47
Quantifying interfraction and intrafraction tumor motion in lung stereotactic body radiotherapy using respiration-correlated cone beam computed tomography. Int J Radiat Oncol Biol Phys (2009) 1.47
Patient preferences for oropharyngeal cancer treatment de-escalation. Head Neck (2012) 1.45
TMPRSS2-ERG status is not prognostic following prostate cancer radiotherapy: implications for fusion status and DSB repair. Clin Cancer Res (2013) 1.45
Improving Outcomes in Resectable Gastric Cancer: A Review of Current and Future Strategies. Oncology (Williston Park) (2016) 1.43
Dosimetric comparison of IMRT vs. 3D conformal radiotherapy in the treatment of cancer of the cervical esophagus. Radiother Oncol (2008) 1.42
Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer. Clin Cancer Res (2012) 1.41
Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir. Hepatology (2009) 1.40
Response to letter to the editor with reference to article "Postoperative intensity-modulated radiotherapy following surgery for oral cavity squamous cell carcinoma: patterns of failure". Oral Oncol (2013) 1.40
Quality of life after parotid-sparing IMRT for head-and-neck cancer: a prospective longitudinal study. Int J Radiat Oncol Biol Phys (2003) 1.39
The radiological diagnosis of hepatocellular carcinoma. Am J Gastroenterol (2010) 1.39
An evidence-based review of poorly differentiated thyroid cancer. World J Surg (2007) 1.38
Natural course of distant metastases following radiotherapy or chemoradiotherapy in HPV-related oropharyngeal cancer. Oral Oncol (2012) 1.38